RMRonaldo Soares Maia

Ronaldo Soares Maia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Ronaldo Soares Maia has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials

    by Bianca Caroline Benedicto, Beatriz Taveira Constantinou, Amauri Moreira Leite Junior, Soraya Hussein Orra, Beatriz Sanches Molina, Tayná Pereira Leite de Almeida, Beatriz Brandão da Silva Navas, Rodrigo Afonso da Silva Sardenberg, Fernando Gonçalves de Almeida, Ronaldo Soares Maia, et al.

    Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.